▲ +149.55% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Galecto in the last 3 months. The average price target is $14.00, with a high forecast of $16.00 and a low forecast of $12.00. The average price target represents a 149.55% upside from the last price of $5.61.
The current consensus among 3 investment analysts is to buy stock in Galecto.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.